Mar 27,2017

AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network® (ORIEN) Avatar Research Program

AbbVie, a global biopharmaceutical company, and M2Gen, a leading health informatics solutions company, announced today that AbbVie has joined the Oncology Research Information Exchange Network® (ORIEN) Avatar Research Program. Launched in April of 2016, the ORIEN Avatar Research Program fosters collaboration among key stakeholders in cancer research with the shared goal of discovering and developing novel therapies in clinical trials. ORIEN Avatar is a collaboration between the 15 leading U.S. cancer hospitals that comprise ORIEN, leading pharmaceutical companies and M2Gen, which manages the program. AbbVie is the fourth pharmaceutical company to participate in the Avatar Program. 

COLLABORATION PARTNERSHIP

#r&d

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 09,2021

M2GEN Announces Collaboration with Microsoft to Advance Bioinformatics Solutions for Oncology

M2GEN today announced it is partnering with Microsoft to advance and scale its unique data-driven solutions for the discovery, research and development of new oncology therapies. Since 2014, M2GEN has collected a dataset comprised of tumor and germline genomic data matched with longitudinal, lifetime-consented clinical data from over 300,000 patients. In that time, M2GEN has transformed this dataset into a vital tool that frictionlessly delivers complex oncology data and analytics solutions to researchers in pharmaceuticals, biotechnology, and academia, leading to breakthroughs in oncology science that can improve cancer patient care. M2GEN will collaborate with Microsoft to quickly and meaningfully enhance this tool into a scaled platform that leverages Azure Synapse Analytics with Microsoft Azure Healthcare APIs to enable broad and deep clinico-genomic analysis capabilities and services. The platform will be built on the foundation of Azure Data Lake Storage Gen2 and Azure Purview, the unified data governance solution. 

COLLABORATION PARTNERSHIP

#product & service

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jun 15,2016

Takeda and M2Gen Collaborate with ORIEN to Speed Clinical Development and Discovery of Cancer Treatments Through Health Informatics

Takeda Pharmaceutical Company Limited and M2Gen, a healthcare informatics solutions company, have established a new collaboration to generate broad genomic data from consenting cancer patients. Under the agreement, Takeda will help build the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program based on the Total Cancer Care Protocol, a prospective observational study enrolling patients with various cancers, and access information generated under this program. The data provided through M2Gen’s ORIEN Avatar Research Program has the potential to enable ORIEN cancer centers to more rapidly find and enroll patients with specific biomarkers into Takeda clinical studies, among others.

COLLABORATION PARTNERSHIP

#r&d

#rwd

View Analyst & Ambassador Comments
Go to original news
Mar 18,2016

PatientsLikeMe and M2Gen Announce Partnership

PatientsLikeMe® and M2Gen® have announced partnership to give patients and researchers a more complete picture of patients’ experiences with cancer treatments and to shed new light on the factors that may affect outcomes and quality of life. The partnership aims to advance cancer research by combining real-world, patient-reported outcomes shared by members of PatientsLikeMe with the molecular and clinical data shared by patients enrolled in the Total Cancer Care® program at Moffitt Cancer Center and The Ohio State University Comprehensive Cancer Center. The combined dataset will give researchers a broader, longitudinal view of the many factors that affect patient outcomes. The collaboration’s initial study is expected to kick off within the next several months and to focus on lung cancer. 

COLLABORATION PARTNERSHIP

#r&d

#rwd

View Analyst & Ambassador Comments
Go to original news
Mar 03,2020

Sema4 and VieCure collaborate to provide real-time patient insights

Health intelligence company Sema4 and artificial intelligence (AI) informatics company VieCure have entered a strategic collaboration to enable oncologists to provide personalised care to the patients. The alliance allows Sema4 scientists to access patient data from the VCurePrecision EMR platform with the consent of the patients and analyse the data using its Centrellis health intelligence platform. Furthermore, it will allow oncologists using the VCurePrecision EMR to access real-time insights that help in point-of-care decision-making and clinical trial identification for patients. This strategic collaboration also enables healthcare providers to recommend Sema4’s molecular testing for cancer through the VCurePrecision platform.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Feb 13,2023

Verana Health Announces Release of Qdata Module for Non-Muscle Invasive Bladder Cancer RWE Analysis

Verana Health—a digital health company elevating quality in real-world data (RWD)—today announced that a Urology Qdata module is available to help support clinical research surrounding non-muscle invasive bladder cancer (NMIBC). Exclusive insights into more than 50,000 de-identified patients with NMIBC are derived from key variables extracted from unstructured clinician notes including diagnosis date, treatments, recurrences, documented T stage, and tumor grade for risk determination. Qdata NMIBC is powered by the American Urological Association's (AUA) Quality Registry (AQUA), the world's largest real-world clinical data registry for urology.

PRODUCT

#rwd

#ai/software

#ml

View Analyst & Ambassador Comments
Go to original news
Feb 27,2023

M2GEN and Zephyr AI Announce Partnership to Better Identify Treatments and Cures for Patients with Cancer

M2GEN, a bioinformatics company accelerating discoveries in oncology research through industry-leading data and analytics, and Zephyr AI, Inc., a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine, today announced a multi-year strategic partnership that will accelerate drug discovery and expanded use investigations for cancer treatments. In this partnership, M2GEN will license its expansive RWD to Zephyr AI, providing the latter with access to the richest clinicogenomic data set available in oncology today. In return, Zephyr AI will become a bioinformatics partner for M2GEN, providing the company with AI and machine learning capabilities to enhance their products and services. 

COLLABORATION PARTNERSHIP

#r&d

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 09,2023

Huma acquires Alcedis, one of the world's leading digital clinical trials companies

Huma Therapeutics Limited has acquired Alcedis GmbH, a leading data-driven clinical research and technology company, to establish an advanced clinical trials division that will offer digital solutions throughout the entire development pipeline, from early stages to Phase IV hybrid and fully decentralized trials.

COLLABORATION MERGERS & ACQUISITION

#data & technology

#rwd

#platform

View Analyst & Ambassador Comments
Go to original news
Jan 10,2023

Development and external validation of a machine learning-based prediction model for the cancer-related fatigue diagnostic screening in adult cancer patients: a cross-sectional study in China

This study aimed to create a CRF prediction model for cancer patients based on routinely obtained data from electronic health records (EHRs) using the 3P model, and externally validate the model with an independent dataset from another hospital. The study concluded that the 3P-based fatigue prediction model can accurately predict the risk of CRF, and that nonlinear algorithms such as Random Forest and Naive Bayes are more suitable for symptom diagnosis and evaluation.

CLINICAL STUDY

#rwd

#big data

#ml

View Analyst & Ambassador Comments
Go to original news
Jan 12,2023

Key Takeaways from ASH 2022: Real-World Data Gets Down to Business

Real-world data is an indispensable tool for therapeutic development and clinical research, as revealed in the 2021 annual meeting of the American Society of Hematology. In this context, COTA contributed research on chronic lymphocytic leukemia and took part in the discussion.

#rwd

#big data

View Analyst & Ambassador Comments
Go to original news
Subscribe to RWD